TITLE

Cyclacel Cutting 28 Staffers, Will Focus on Sapacitabine

AUTHOR(S)
Moran, Nuala
PUB. DATE
September 2008
SOURCE
BioWorld International;9/24/2008, Vol. 13 Issue 39, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the decision of Cyclacel Inc. to reduce its British research and development operations and close its facility in Cambridge as part of a restructuring effort. A total of 28 staff members will leave the company, with 17 in the research base. President Spiro Rombotis says the decision to restructure was a difficult one but added the move would streamline effort and speed the development of the clinical portfolio. The company is also extending the Phase II study in acute myeloid leukemia.
ACCESSION #
34517441

 

Related Articles

  • Antisoma Shares Tank 64% as AML Drug Fails in Phase III. Moran, Nuala // BioWorld Today;2/1/2011, Vol. 22 Issue 21, p1 

    The article reports on a 64% decline in shares of Antisoma plc following the failure of its two clinical programs. The company's lead product AS1413 failed in a pivotal Phase III trial in secondary acute myeloid leukemia (AML), while a Phase IIb trial of AS1411 in AML was halted following an...

  • MGI PHARMA/METHYLGENE BEGIN CLINICAL TRIAL OF MG98.  // Worldwide Biotech;Mar2002, Vol. 14 Issue 3, p8 

    Reports on the clinical trial initiated by MGI Pharma Inc. and MethylGene Inc. on MG98, a DNA methyltransferase inhibitor for patients with advanced myelodysplasia or acute myeloid leukemia.

  • Dr Frassoni’s paper was shown to Dr Sue Richards, who has commented as follows. Richards, S // Bone Marrow Transplantation;3/1/2000, Vol. 25 Issue 5, p472 

    Offers observation on a problem of applying the results of randomized trials to the individual patient with acute myelocytic leukemia (AML). Description on randomized trials; Reason for not receiving a transplant.

  • Randomised studies in acute myeloid leukaemia: the double truth. Frassoni, F // Bone Marrow Transplantation;3/1/2000, Vol. 25 Issue 5, p471 

    Comments on randomized studies in acute myeloid leukaemia (AML). Three major therapeutic options for AML; Major problems faced by reported studies; Main reason for publishing the results of clinical trials in major scientific journals.

  • Acute megakaryoblastic leukemia: experience of GIMEMA trials. Pagano, L.; Pulsoni, A.; Vignetti, M.; Mele, L.; Fianchi, L.; Petti, M.C.; Mirto, S.; Falcucci, P.; Fazi, P.; Broccia, G.; Specchia, G.; Di Raimondo, F.; Pacilli, L.; Leoni, P.; Ladogana, S.; Gallo, E.; Venditti, A.; Avanzi, G.; Camera, A. // Leukemia (08876924);Sep2002, Vol. 16 Issue 9, p1622 

    The objective of the study was to evaluate the incidence, characteristics, treatment and outcome of acute megakaryoblastic leukemia (AMeL) in patients enrolled in GIMEMA trials. Between 1982 and 1999, 3603 new consecutive cases of AML aged over 15 years were admitted to GIMEMA trials. Of them,...

  • Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93. Lehrnbecher, T.; Varwig, D.; Kaiser, J.; Reinhardt, D.; Klingebiel, T.; Creutzig, U. // Leukemia (08876924);Jan2004, Vol. 18 Issue 1, p72 

    Infections still remain a major cause of therapy-associated morbidity and mortality in children with acute myeloid leukemia (AML). To improve supportive care measurements, detailed information on frequency and characteristic features of infectious complications is needed. We retrospectively...

  • Drug Shortages Delay Cancer Clinical Trials. Goozner, Merrill // JNCI: Journal of the National Cancer Institute;Jun2012, Vol. 104 Issue 12, p891 

    The article discusses how drug shortage have slowed down a clinical trial. It compares the survival rate from clofarabine to the standard regimen of cytarabine and daunorubicin for patients with acute myeloid treatment (ACL). Causes of these shortages are economics of drug pricing, incentives...

  • Clinic Roundup.  // BioWorld Today;12/27/2012, Vol. 23 Issue 249, p8 

    The reports on the Phase III trial initiated by Celator Pharmaceuticals Inc. for its CPX-351 liposome injection as a first-line therapy of acute myeloid leukemia.

  • Antisoma Shares Tank as AML Drug Fails in Phase III.  // Bioworld Week;2/7/2011, Vol. 19 Issue 6, p3 

    The article reports on the failure of two clinical programs of Antisoma PLC such as its AS1413 lead product to treat secondary acute myeloid leukemia during its Phase III trial and the Phase II trial of AS1411 in AML during an interim analysis.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics